TG Therapeutics Inc annual shares outstanding for fiscal 2025 was 161 million shares, an increase of 0.6% from 160 million shares in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Shares Outstanding (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (M) | — | 161M | 160M | 149M | 135M | 132M | 115M | 88M | 75M | 62M | 49M | 46M | 34M | 25M | 13M | 2M | 0M | 0M | 0M | 0M | 0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Shares Outstanding (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (M) | — | 160M | 159M | 161M | 163M | 163M | 160M | 161M | 159M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More TGTX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow
All TGTX financial statements → Interactive TGTX charts →
About TickerBase · Data methodology & sources · Privacy · Terms